23Strands is standing in solidarity in the fight against ovarian cancer. Ovarian cancer remains one of the most fatal cancers affecting women. Globally, a woman or girl who is diagnosed with ovarian cancer faces a 49% chance of surviving the next five years. Despite this, research in ovarian cancer persists to be disproportionately low in comparison to other fields of oncology.

As a genomic research company, 23Strands aims to spread awareness of the greater need for funding, and highlights how its work in genomic sequencing may assist in improving ovarian cancer treatments to enhance quality of life.

23Strands participates in the fight against ovarian cancer through its comprehensive genetic profiling of tumour tissue, and by extracting relevant data that reveals possible targets for precision drug therapy. The team strives to give clinicians personalised insight to improve patient pathways. 23Strands’ on-going commitment against ovarian cancer through, for example White Shirt Day, reflect its ambitious quest to tackle cancer and other diseases through its genetic research.